文献速递心力衰竭与心肌病

HELIOS-B 试验:转甲状腺素蛋白淀粉样变心肌病患者的门诊心力衰竭恶化

Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial.
PubMed 文献 · J Am Coll Cardiol · 2024-11-18

HELIOS-B 试验评估了转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)患者门诊心力衰竭恶化(口服袢利尿剂强化或启用)的临床与预后意义,以及 vutrisiran 对其的影响。结果显示门诊心衰恶化频繁发生(49.1% 至少一次),与全因死亡和心血管事件风险增加相关,而 vutrisiran 较安慰剂降低了门诊心衰恶化率及复合终点风险。

要点

  • ATTR-CM 患者门诊心衰恶化常见,与死亡和心血管事件风险增加相关。
  • vutrisiran 可降低门诊心衰恶化率及包含死亡、心血管事件和门诊心衰恶化的复合终点风险。
  • 门诊心衰恶化可作为监测疾病进展和评估治疗效果的实用指标。

核心结论

  • 在 HELIOS-B 试验的 ATTR-CM 患者中,门诊心衰恶化频繁发生,与死亡率增加相关,且被 vutrisiran 降低。

主要发现

  • 321 例(49.1%)发生至少一次门诊心衰恶化,245 例(37.5%)发生至少一次心血管事件,120 例(18.3%)死亡,237 例(36.2%)无事件。
  • 门诊心衰恶化患者全因死亡和心血管事件风险增加(HR 2.58;95%CI 2.04-3.27),全因死亡风险增加(HR 2.45;95%CI 1.70-3.52)。
  • 门诊心衰恶化患者 6 分钟步行距离和 KCCQ-OS 评分恶化更明显,NT-proBNP 升高更显著。
  • 双盲期内,vutrisiran 较安慰剂降低门诊心衰恶化率(相对率比 0.66;95%CI 0.56-0.78)。
  • vutrisiran 较安慰剂降低全因死亡、心血管事件和门诊心衰恶化复合终点风险(HR 0.69;95%CI 0.57-0.83)。

临床怎么用

  • 门诊心衰恶化(口服袢利尿剂强化或启用)可作为 ATTR-CM 患者疾病进展和预后评估的简便指标。
  • vutrisiran 治疗可减少门诊心衰恶化,支持其用于改善 ATTR-CM 患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods are needed to monitor patients and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM. OBJECTIVES: This study aimed to assess the clinical and prognostic significance of and the effect of vutrisiran treatment on outpatient worsening HF in patients with ATTR-CM from HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy). METHODS: Associations between outpatient worsening HF and a composite of all-cause mortality and recurrent cardiovascular (CV) events (CV hospitalizations and urgent HF visits), all-cause mortality, and other disease progression-related endpoints were evaluated. The impact of vutrisiran over 36 months on outpatient worsening HF and an expanded composite of all-cause mortality, recurrent CV events, and outpatient worsening HF was also assessed. RESULTS: Overall, 321 patients (49.1%) had ≥1 outpatient worsening HF, 245 (37.5%) had ≥1 CV event(s), and 120 (18.3%) died; 237 patients (36.2%) had no events. Patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events (HR: 2.58; 95% CI: 2.04-3.27) and all-cause mortality (HR: 2.45; 95% CI: 1.70-3.52), as well as a greater deterioration in 6-minute walk test distance and Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and a greater increase in N-terminal prohormone of B-type natriuretic peptide. In recurrent event analyses over the double-blind period, vutrisiran vs placebo reduced the rate of outpatient worsening HF (relative rate ratio: 0.66; 95% CI: 0.56-0.78). Vutrisiran also reduced the risk of the composite of all-cause mortality, CV events, and outpatient worsening HF vs placebo (HR: 0.69; 95% CI: 0.57-0.83). CONCLUSIONS: Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, was associated with increased mortality, and reduced by vutrisiran. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Fontana M, Maurer MS, Gillmore JD, et al. Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial. J Am Coll Cardiol. 2024. PMID: 39566871. doi:10.1016/j.jacc.2024.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。